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GLOSSARY 
 
AWMI  - Anterior wall myocardial infarction 
CAD   - Coronary artery disease 
DM   - Diabetes Mellitus 
ESV   - End Systolic Volume 
EDV   - End Diastolic Volume 
LVEF   - Left Ventricular Ejection Fraction 
LVIDs  - Left Ventricular Internal diameter in systole 
LVIDd  - Left Ventricular Internal diameter in diastole 
LV Thrombus - Left Ventricular Thrombus 
MR   - Mitral Regurgitation 
FS   - Fractional Shortening 
SHT   - Systemic Hypertension 
WMSI  - Wall Motion Score Index 
RWMA  - Regional Wall Motion Abnormality 
STEMI  - ST Elevation Myocardial Infarction 
ICCU   - Intensive Coronary Care Unit 
Echo B  - Baseline Echo 
Echo 14  - Echo on Day 14 
Echo 28   - Echo on Day 28 
INTRODUCTION 
 
 Left ventricular thrombus is common after acute myocardial 
infarction; in different studies, the incidence of left ventricular thrombi 
has been reported varying from 28% to 54 %. (1-9)With the advent of  
systemic thrombolysis as standard treatment in acute myocardial 
infarction, few studies reported the effects of thrombolytic agents on 
ventricular thrombi, showing that thrombolytic therapy reduces their 
frequency. (10-13) 
 
          However the impact of thrombolysis on the incidence of LV 
thrombi has been incompletely investigated.  In this study, a wide 
patient population with STEMI was evaluated through serial echo to 
identify whether any significant association does exist between wall 
motion abnormalities and thrombus formation.  The influence of co-
morbid factors (DM, AGE, SEX, SMOKING, SYSTEMIC 
HYPERTENSION, DYSLIPIDEMIA, FAMILY HISTORY OF CAD) were 
also evaluated as possible predictors of LV clot formation.   
REVIEW OF LITERATURE 
 
 Left ventricular thrombus commonly follows an acute myocardial 
infarction, particularly when it involves a large area of myocardium of 
the apex and anterior wall. The main clinical implication of left 
ventricular thrombus is related to possible embolic complications, most 
importantly affecting the cerebral circulation, that deleteriously 
influence the clinical outcome of approximately 10% of patients 
surviving the acute phase of an infarction. 
 
The Diagnosis of Thrombus: 
 The diagnosis of thrombus is based on the detection of an echo 
dense mass with defined margins, clearly identifiable throughout 
the cardiac cycle, adjacent to asynergic Myocardium, visible in at 
least two different echo Cardiographic views and distinguishable 
from other Cardiac structures or artifacts (Asinger et al 1981a, 
Stratton et al 1982, Visser et al 1983a, Weinreich et al 1984). 
Detection of adjacent myocardial asynergy is a necessary precondition 
when diagnosing left Ventricular thrombus following an acute 
Myocardial infarction (Asinger et al 1981b). The thrombi are located 
most frequently but not exclusively in the left ventricular apex (Asinger 
et al 1981a, Stratton et al 1982, Visser et al 1983a, 1985). The 
presence of apical dilatation or dyskinesia and the greater degree of 
Myocardial necrosis which more frequently characterizes an anterior 
as opposed to an inferior infarction predisposes to a greater focal 
stasis of intra-cavitary blood and to the development of thrombus 
(Yater et al 1951, Jordan et al 1952, Asinger et al 1981b,); 
Consequently, most thrombi develop in the left ventricular apex of 
patients with anterior myocardial infarction.  
 
 In addition, normal and pathological structures present near the 
left ventricular apex must be differentiated from thrombus, The 
recognition of papillary muscles can be aided by identifying them in 
their usual site and excluding wall motion abnormalities. Muscle 
trabeculae are often associated with left ventricular hypertrophy and 
may appear as muscular bridges across the ventricular cavity. The 
detection of an echo-free space on each side of this structure may 
exclude this mis-interpretation. Chordal structures (true chordae 
tendineae or chordal-like structures) can be distinguished from 
thrombus by the absence of adjacent asynergic myocardium, the 
detection of an echo-free area on each side of them and their normal 
straightening motion during diastole. Finally, when examining the left 
ventricular cavity, an incorrect tangential visualization of the apex 
simulating the presence of a thrombus must be avoided. 
 
 Echocardiographic evaluation of the cardiac apex should be 
obtained with the patient in the lateral decubitus position and the 
transducer placed at the point of maximal apical impulse. Slight 
changes in transducer position may be necessary for a complete 
examination of the cardiac apex, whose geometry can be altered by an 
aneurysmatic dilatation or a dyskinetic motion. 
 
 At present, the sensitivity and specificity of echocardiography in 
the diagnosis of left ventricular thrombus can be considered as being 
approximately 95 and 88%, respectively (Ezekowitz et al 1982, 
Stratton et al 1982, Visser et al 1983a, Domenicucci et al 1987.) 
 
     Inspite of correct  methodology and a thorough echo  search for 
thrombus, false negative diagnosis may occur.  These are normally 
attributable to the small dimension of the intracardiac mass; a thin, 
layered thrombus with a maximum thickness of less than 0.6cm 
will not be identified (Mikell et al 1982a) 
 
Other Diagnostic Techniques: 
     With regard to other techniques proposed for the evaluation of  left 
ventricular thrombus Indium 111 platelet scintigraphy should be 
considered complementary to echo, since it can detect platelet 
turnover on the thrombus surface and appears suitable to assess the 
effects of anti-thrombotic  drugs(Ezekowitz et al  1982);however, 
inspite of its high specificity this method is not cost effective and is time 
consuming, in addition it has a low sensitivity, being unable to show 
hematologically inactive thrombi. The low feasibility and repeatability 
and the high cost of CT and MRI (notwithstanding their good 
diagnostic accuracy), make these methods advisable only when initial 
echo studies are technically inadequate or equivocal. 
 
PATHOGENETIC DETERMINANTS OF THROMBUS FORMATION 
 From the initial observation that thrombus is always associated 
with left ventricular wall motion abnormalities (Asinger et al 1981b), 
further studies (Stratton et al 1982, Visser et al 1983b, Weinreich et al 
1984, Domenicucci et al 1987) have clarified the relationship between 
thrombus occurrence and the site and size of myocardial infarction. 
Patients with anterior infarcts who have a larger extent of necrotic 
myocardium, particularly with aneurysms, are at a higher risk of 
thrombus formation than those with infarction in other areas or with a 
lesser degree of asynergic myocardium. The hypothesis is that 
apical dyskinesia and the aneurysmic dilatation of the left 
ventricular apex might predispose to regional stasis of blood and 
consequently to thrombus development (Yater et al 1951, Jordan et 
al 1952, Asinger et al 1981b, Visser et al 1983b). 
 
 Two-dimensional echocardiography can demonstrate the 
presence of unusual patterns of intra-cavitary echoes attributable to 
blood stasis, detectable in areas of severe apical dysfunction and 
predictive of thrombus development. These patterns appear as 
spontaneous ‘smoke-like’ echoes without defined margins, with rapid 
changes in configuration and acoustic intensity over a short time. More 
recently, the employment of qualitative and quantitative analyses with 
Doppler techniques has further addressed the relationship between 
flow abnormalities, attributable to blood stasis, and a higher 
occurrence of thrombus (Delemarre et al 1990). 
 
 Therefore, the Echo-Cardiographic analysis of left ventricular 
wall motion abnormalities and of blood flow characteristics can allow 
the identification of those patients who are at higher risk of developing 
thrombus after acute myocardial infarction. 
 
Incidence And  Time Of Appearance Of Thrombus 
 The feasibility and repeatability of cardiac ultrasound, together 
with its high diagnostic accuracy, make this technique an ideal tool for 
determining the incidence and the time of appearance of left 
ventricular thrombi after acute myocardial infarction.  The overall 
occurrence of left ventricular thrombus after an isolated inferior 
myocardial infarction has been estimated as less than 1% of the 
studied patients (Asinger et al 1981a, Visser et al 1983b, Weinreich et 
al 1984, Keren et al 1990) and is found only where aneurysmatic 
dilatation of the inferior wall occurs (Straton et al 1982, Wenreich et al 
1984). Therefore, the clinical relevance of left ventricular thrombus in 
this condition appears negligible. On the other hand, the incidence of 
thrombi after anterior myocardial infarction ranges from approximately 
30% to nearly 60% of the patients studied (Asinger et al 1981a, Visser 
et al 1983b, Davis & Ireland 1986, Domenicucci et al 1990). Some 
series have shown a favorable effect of both anticoagulant 
(Norderhaug et al 1985) and fibrinolytic treatment. (Lupi et al.) in 
reducing the rate of thrombus formation. In a study by Vecchio et al in 
1991, no difference in thrombus occurrence was observed in  
thrombolysed patients assigned, in a random mode, either to initial 
streptokinase or rt-PA therapy followed or not by subcutaneous 
heparin. 
 
 As far as the time of appearance is concerned, nearly 50% of 
thrombi develop within the first 2 days after acute infarction, with 
almost 95% being present within 2 weeks. (Davis & Ireland 1986, 
Funke Kupper et al 1989, Domenicucci et al 1990). The late 
development of thrombus, at more than 1 month after infarction, has 
been reported in approximately 10% of cases (Visser et al 1983b, 
Domenicucci et al 1990, Keren et al 1990).  Spirito et al (1985) found a 
relationship between the early development of thrombus (i.e. within 48 
hours of anterior infarction) and a higher global mortality; more recent 
evaluations of larger patient populations have further confirmed that 
early thrombus formation is a marker of higher mortality, using either-
in-hospital death (Domenicucci et al 1990) or global mortality rates 
(Funke Kupper et al 1989) as end-points. Consequently, after acute 
anterior myocardial infarction, an early echocardiographic search for 
left ventricular thrombus, performed within 48 hours of symptom onset, 
may be useful in attempting to identify a subgroup of patients with a 
poorer prognosis. 
 
Morphological   Patterns 
 2D – dimensional echocardiography is the best method for     
non–invasively assessing the anatomical characteristics of thrombi 
and to follow their possible variations with time. 
 
 With regard to shape, left ventricular thrombi can be subdivided 
into mural or protruding. Mural thrombi  have a flat configuration, with 
the free margin usually showing a concave curvature, parallel to the 
adjacent endocardial surface. A thrombus is considered protruding 
when it predominantly projects into the left ventricular cavity and the 
thrombus –blood interface demonstrates a curvature that is convex to 
the adjacent endocardium. Detection of mobility  is   based on the 
observation of motion of a portion of the thrombus which is 
independent of that demonstrated by the adjacent myocardium. 
 
 The clinical relevance of thrombus anatomy has been 
emphasized in recent studies which have shown a higher embolic 
potential for protruding and / or mobile thrombi when compared with 
mural, non – mobile thrombi (Haugland et al 1984, Visser et al 1985, 
Johannessen et al 1988  
 
Spontaneous variations in thrombus shape, from protruding to 
mural configuration or vice versa, can be observed in approximately 
40% of thrombi developed after anterior myocardial infarction 
(Domenicucci et al 1987). Changes in thrombus mobility are also 
frequently noted (Domenicucci et al 1987, Funke Kupper et al 1989). 
The majority of changes in thrombus anatomy occur in the initial time 
period after acute infarction: in our experience, nearly 90% of the 
variations in shape and mobility were detected within 1 month  after 
infarction. 
 
 As far as the relationship between thrombus age and its 
morphological characteristics is concerned, patterns of protruding 
shape are mostly detected in the early phase after acute infarction, 
while in older thrombi a mural configuration appears to be predominant 
(Domenicucci et al 1987, Keren et al 1990). 
 
 Thrombus mobility is detectable in approximately one third of 
thrombi (Domenicucci et al 1987) and is usually observed only in the 
early period after infarction : nearly 90% of the mobile thrombi noted in 
the first few days after an acute infarction showed no mobility at 1 
month of follow up, while all mobility was completely absent in the 
Echo Cardiographic examination performed at more than 6 months 
after infarction. Due to its peculiar transience and spontaneous 
variability, a reliable assessment of the incidence and evolution of 
thrombus mobility needs serial echocardiographic examinations 
repeated at short time intervals. Conceivably, the more frequent 
observation of mobility and the protruding configuration of left 
ventricular thrombus in the first few months after acute infarction is 
related to the occurrence of most embolic complications in the same 
period. For this reason, an accurate and serial echocardiographic 
evaluation of thrombus anatomy in this period is advisable. 
 
Dimension 
 Echocardiography permits an immediate, qualitative assessment 
of thrombus dimension and extent within the left ventricular cavity. 
Moreover, planometry of the thrombus may easily be obtained by the 
direct digitization of the frozen frame on the screen. However, the 
reliability of such a quantitative evaluation is limited by the inherent 
three dimensional conformation of thrombus. Serial evaluation of 
thrombus dimension with cardiac ultrasound has been proposed as a 
useful and repeatable method for assessing the effects of long-term 
antithrombotic treatment (Stratton & Ritchie 1984). In particular the 
detection of a reduction in the maximal thickness of thrombus of 
over 5mm or complete thrombus resolution has been considered 
as attributable to the on-going antithrombotic therapy. However, it 
must be pointed out that reduction in thrombus size or even its 
resolution may occur spontaneously in a significant percentage of 
patients (Spirito et al 1885, Keren et al 1990). Therefore, the presence 
of such spontaneous variations in thrombus dimension must be taken 
into account when cardiac ultrasound is used for assessing the 
efficacy of chronic antithrombotic treatment. 
 
 Conversely, echocardiography is a unique tool for evaluating the 
acute, sometimes dramatic, effects of fibrinolytic treatment given to 
resolve a thrombus with the morphological characteristics consistent 
with high embolic potential, such as protrusion and free mobility. The 
complete resolution of the thrombus or a significant reduction in its 
size has been reported in   majority of cases (Kremer et al 1985, Keral 
et al 1990). Other than documenting the lysis of thrombus, 
echocardiography can permit the visualization in real time of on-going 
thromboembolization with thrombus fragmentation and the subsequent 
appearance of thrombus fragments in the left ventricular outflow tract. 
Clinical evidence of thromboembolization attributable to thrombolytic 
treatment has been reported (Keren et al 1990) and it has been 
suggested that the risk/benefit ratio of this procedure still remains to be 
determined. 
 
 
 
ACOUSTIC CHARACTERIZATION OF THROMBUS 
 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
 Cardiac ultrasound can allow both a qualitative and quantitative 
characterization of a left ventricular thrombus. Usually the echodensity 
of a thrombus is greater that that of the adjacent myocardium. The 
observation of an acoustically distinct structure in an area of 
myocardial aysnergy may itself represent a diagnostic criterion for 
discriminating a thin but otherwise hardly recognizable thrombus from 
the adjacent endocardium. Variations in reflective intensity within a 
thrombus may indicate differences in its histological composition or 
architecture (Mikell et al 1982a). Thrombi may appear as layered 
structures showing variations in their ehcodensity usually the most 
echo dense layer corresponds to the thrombus-blood interface and 
conceivably represents the last-formed portion of thrombus. This 
acoustic feature is commonly seen in fresh thrombi with a mural 
configuration. On the other hand, the opposite pattern may be 
detected in the presence of a freely mobile, swirling portion of a 
protruding thrombus, which demonstrates a lower echodensity and 
less distinct intra-cavitary margins. 
 Serial echocardiograms performed in the same patient 
occasionally demonstrate temporal variation in the acoustic 
characteristics of a thrombus. These may occur spontaneously or may 
be due to antithrombotic treatment.  The spontaneous liquification of a 
thrombus is characterized by the presence of an echo-free space 
within the thrombosis substance, followed by a subsequent return to a 
more homogneous echodensity. Similar variations in the acoustic 
patterns are also detectable during acute treatment with fibrinolysis. 
 
 More recently, a technique for assessing the two-dimensional 
spatial distribution of echo amplitudes in a region of interest, known as 
quantitative texture analysis, has been employed to characterize the 
acoustic properties of intracardiac thrombi. Preliminary data from these 
studies would seem to indicate that assessment of tissue 
characteristics may distinguish fresh from old thrombi and help to 
identify those thrombi that are at a higher risk of systemic 
embolization. (Lloret et al 1985, Bellotti et al 1991). If these results are 
confirmed, they open a new possible application of cardiac ultrasound 
in the definition of the embolic potential of left ventricular thrombi. 
 
PREVENTION OF EMBOLIC COMPLICATIONS 
Contribution Of Cardiac Ultrasound 
 . The systematic prevention and treatment of left ventricular 
thrombus with anticoagulants still appears questionable. First such 
treatment does not totally prevent thrombus development, and late 
thrombus formation or recurrence after discontinuation of the drug has 
been reported. (Asinger et al 1981a, Visser et al 1983a, Keren et al 
1990). Secondly, the potential benefits of this treatment must be 
weighed against the hazards of possible haemorrhagic complications. 
For these reason, it would be of benefit if echocardiography could 
identify those patients at higher risk of embolization in order to select 
out the subgroup of patients who might benefit from antithrombotic 
treatment, thus minimizing the danger of haemorrhagic complications. 
Although the anatomical instability of thrombi may limit the value of 
previous echo cardiographic studies performed in order to define the 
morphological markers of higher embolic potential, from the analysis of 
the data available so far, it is reasonable to state that a protruding 
pedunculated thrombus with a freely mobile portion represents a very 
likely source of embolization and would constitute an indication for 
anti-thrombotic treatment, if no major contraindications are present. As 
far as the effects of such treatment are concerned, cardiac ultrasound 
can be employed to verify the possible success of anticoagulant 
therapy, considered as either resolution of thrombus or induced 
favorable changes of its morphology into a mural, non-mobile 
configuration. This finding can be a reason for stopping the treatment, 
however; further echocardiography control is advisable in order to 
detect the potential recurrence of thrombi with high embolic risk. 
 
Best Timing For  Echocardiographic  Evaluation Of Left Ventricular 
Thrombus. 
Due to the anatomical instability of left ventricular thrombus, an 
accurate assessment of its natural history with cardiac ultrasound 
needs repeated examinations performed at short time intervals, 
particularly in the first month after infarction, when most morphological 
variations occur. However, as far as the clinical definition of thrombus 
is concerned, a limited number of echocardiograms appear suitable to 
identify the most crucial events during its dynamic evolution. 
 
After anterior myocardial infarction, an early examination 
should be performed within 24-48 hours of symptom onset, this 
would allow the detection of the abnormalities in left ventricular wall 
motion and flow patterns, which identify a subgroup of patients more 
prone to thrombus formation. In addition, the observation of early 
thrombus development may help in discriminating patients with a 
poorer clinical profile and a higher risk of death. 
 
 A second echocardiogram should be obtained 10 to 15 days 
after infarction or at the time of hospital discharge. This evaluation 
would allow the detection of thrombi of high embolic potential. 
 
Finally, a third echocardiogram is advisable 1- 3 months 
after the infarction. 
  
 
 
ECHOCARDIOGRAM 
ECHOCARDIOGRAM 
 
Patients were serially evaluated by 2D and Doppler 
Echocardiography in the following sequence: within 48hrs, day 14 and 
at 1month after infarction. All examinations were performed using a 
ALOKA SSD 2000 machine 2.5Mhz transducer and the were stored 
on VHS tapes for later analysis. 
 
 The diagnosis of Left Ventricular Thrombosis was made when 
an echodense mass with a margin distinct from the left ventricular wall 
was detected within the left ventricular cavity and was visible 
throughout the cardiac cycle in atleast two different echocardiographic 
views and associated with asynergy (akinesis or dyskinesis) of the 
adjacent myocardium.  
 
 During recording, particular care was taken to obtain all possible 
views and to optimize depth and gain settings in order to minimize the 
possibility of false positive or false negative readings. B-colour was 
also used in equivocal situation. Each echocardiographic study was 
interpreted independently by two echocardiographers who were 
blinded to patients’ clinical data. 
 
 Left ventricular end–diastolic and end–systolic volumes and 
ejection fraction were determined from apical two-and four chamber 
views using the Simpson’s biplane formula, according to the 
recommendation of the American Society of Echocardiography. 
Tracing of endocardial borders in end diastole and end systole were 
performed on the ALOKA machine in the technically best cardiac 
cycle. The volumes were normalized for Body surface area and 
expressed as indexes. 
  
In order to calculate the wall motion score index, the left 
ventricle was divided into 17 segments. Segmental wall motion was 
graded as follows: normal motion at rest (Score1), hypokinetic – 
marked reduction in endocardial motion and systolic thickening (Score 
– 2), akinetic – virtual absence of inward motion and systolic 
thickening (Score – 3) and dyskinetic – paradoxical wall motion away 
from the centre of the left ventricle in systole (Score – 4). The Wall 
motion score index was calculated by summation of individual 
segment scores divided by the number of interpreted segments.  
 
Pulsed-wave and color Doppler flow mapping were used for the 
detection and grading of mitral regurgitation. Severity of mitral 
regurgitation was assessed semi quantitatively according to the length 
of the turbulent flow jet into the left atrial cavity. 
 
 Myocardial necrosis, once established, results in a permanent 
WMA. The degree of transmural involvement required before wall 
motion becomes abnormal is approximately 20%. The implication of 
this is that non-transmural  MI will result in hypokinesis or akinesis of 
the wall, even though the majority of the myocardial mass may still be 
perfused and viable. (Braunwald 7th Edn. Pg. 242-245) 
 
 In clinical Echo, a RWMA, conforming to a known coronary 
distribution is the hall mark of acute ischemia or MI. After successful 
reperfusion, WMA typically will resolve. The time course over which 
they resolve is variable and may range from 12 hours to 2 weeks. 
Typically, WMA recover within 72 hours if blood flow has been restored 
in a timely fashion. (Braunwald 7th Edn. Pg. 243) 
 
 Areas of abnormal regional wall motion are observed almost 
universally in patients with Myocardial infarction and the degree of 
WMA can be categorized with a semi quantitative WMSI. Of note, 
abnormal wall motion  is less often noted on echocardiography. When 
the infarction is small and the age of RWMA can't always be 
determined, LV function estimated from 2D echo correlates well with 
measurements from angiography and is useful in establishing 
prognosis after Myocardial infarction. Furthermore, the early use of 
echo can aid in the early detection of potentially viable but stunned 
myocardium (contractile reserve), residual provocable ischemia, 
patients at risk for the development of CHF after myocardial infarction, 
and mechanical complications of Myocardial infarction. (Braunwald 7th 
Edn. Pg. 1162 & 1163) 
 
 Prospective studies have suggested that patients who develop a 
mural thrombus early (with in 48 to 72 hours of infarction) have an 
extremely poor early prognosis, (Ref :- Barbera S, Hillis LD : Echo 
cardiographic recognition of LV mural thrombus Echocardiography 16 : 
289, 1999). with a high rate of mortality from the complications of a 
large infarction(shock, reinfarction, rupture and ventricular 
tachyarrythmia), rather than embolism  from the LV thrombus. 
(Braunwald 7th Edn. Pg. 1215) 
 
Management Of LV Thrombus 
 I.V. Heparin (apTT 1:5-2) followed by 3-6 months Warfarin. In  
(1) an embolic event has already occurred. (or) 
(2) The patient has a large amount whether or not a 
thrombus is visualized echocardia graphically. 
(3) Other than the AWMI if a thrombus or large WMA is 
detected. 
 
Aspirin, although probably not capable of affecting thrombus 
size in most patients, may prevent further platelet deposition on 
existing thrombi and also is protective against recurrent ischemic 
events. (Braunwald 7th Edn. Pg. 1215) 
 
 
  
 
 
AIMS OF THE STUDY 
AIMS OF THE STUDY 
 
 To study the incidence / prevalence of intra-cavitary thrombus in 
STEMI patients following thrombolysis. 
 
 To establish the role of Early Echo Cardiogram in studying the 
relationship between wall motion abnormality and thrombus 
formation. 
 
 To evaluate associated Co-morbid condition (Hypertension, 
Diabetes Mellitus, Smoking, Age and Sex, Area of infarct etc) in 
relation to intra-cavitary thrombus formation in post – 
thrombolytic STEMI patients. 
  
 
 
 
MATERIALS AND 
METHODS 
MATERIALS AND METHODS 
 
 
Materials 
 Settings  : Intensive Coronary Care Unit (ICCU) 
     Government Rajaji Hospital 
     Madurai 
 
 Type of Study : Prospective Cohort study 
 
 Period of Study : August 2005 – July 2006 
 
 Sample Size : 144 patients 
 
 Consent  : Informed consent was obtained from all  
Patients or relatives 
 
 
 Inclusion Criteria 
All patients admitted to ICCU with STEMI 
STEMI irrespective of the type, age and the extent of successful 
thrombolysis were included in this study. 
 
 
 
 
Exclusion Criteria 
 Previous H/O thrombolysis 
 Previous H/O intracavitary thrombus 
 Arrythmias 
 Myocarditis 
 LBBB 
 Old MI 
 Acute MI with Median delay > 24 hours 
 
Laboratory Materials 
 The following investigations were done for all the patients. 
 Hb, TC, DC, ESR 
 Blood sugar, urea, creatinine, serum electrolytes, lipid 
profile, ECG 
 Enzyme markers CKMB – TOTAL 
Baseline Echo was estimated on Day 1, Day 14 and then 
on Day 28. 
 
 Patients were monitored and managed in ICCU as per the 
standard guidelines. Appropriate biochemical tests were done 
according to their clinical condition and underlying medical diseases. 
 
METHODS 
 
We have prospectively evaluated 144 consecutive patients with 
first acute myocardial infarction who met the following criteria: all cases 
of STEMI  irrespective of the type of infarction, age or sex of the 
patient. 
 
 Baseline characteristics of patients enrolled in the study are as 
follows:age,sex,risk factors(smoking, SHT,DM,Dyslipidemia,Family H/o 
CAD,Menopause),median delay less than 24hrs,presence of MR and 
whether or not patient underwent thrombolysis. 
 
Clinical assessment of patient’s cardiovascular status was made 
according to the Killip classification. 
 
Therapy 
Thrombolytic therapy (iv streptokinase 1.5million IU over 30 to 
60 minutes) was administered in 110/144 (76.4%) patients. The 
remaining patients did not receive thrombolytic therapy due to some 
contraindications. 
Definitions 
1. STEM 1 → ST Elevation  
a. 1 mm in Limb leads 
b. 2 mm in precordial leads 
 
2. Successful thrombolysis → Resolution of chest pain x > 50% 
reduction of ST elevation 
 
3. Unsuccessful thrombolysis → Non resolution of chest pain 
and < 50% reduction of ST elevation 
 
4. Median Delay → Time interval between onset of chest pain to 
admission in ICCU. 
 
5. Killip Classification 
Class I:No signs of pulmonary and venous congestion 
Class II:Moderate heart failure as evidenced by rales at the 
lung bases,S3 gallop,tachypnea or signs of right heart failure 
including venous and hepatic congestion 
Class III: Severe heart failure, pulmonary edema 
Class IV:Shock with systolic pressure<90mmHg and 
evidence of peripheral cyanosis, mental confusion and 
oliguria. 
 
6. Thrombolytic Agent and dose → Streptokinase dose I.V. 1.5 
million units in 100 ml of normal saline within 1 hour. 
 
7. Antithrombotic effect  
a. Heparin 
b. Clopidogrel 
c. Warfarin 
 
8. Higher Median Delay: Median delay>12hrs but < 24hrs. 
 
Clinical and biochemical data were collected using a Proforma. 
All the relevant details were fed into a computer. End point of the study 
was discharge from ICCU. 
 
Computer Analysis of data was done using the software 
epidemiological information package – 2002 developed by centers for 
disease control and prevention, Atlanta in collaboration with WHO. 
 Chi – square test was used for tests of significance. 
  
 
 
 
ANALYSIS AND RESULTS 
ANALYSIS AND RESULTS 
 
 144 patients of Acute Coronary Syndrome admitted in ICCU, 
Government Rajaji Hospital, Madurai were included in the study. 
 
CHARACTERISTICS OF STUDY CASES 
 
Table 1 
Age distribution of the Study Group 
 
Patients Age Group 
No. % 
21-30 3 2.1 
31-40 17 11.8 
41-50 41 28.5 
51-60 46 31.9 
> 60 37 25.7 
Total 144 100 
Mean 57.6 
S.D. 12 
 
Majority of patients in the study group belonged to 4th and 5th decade. 
  
 
 
Table 2 
 
Patients Sex 
No. % 
Male 134 93.1 
Female 10 6.9 
 
Male formed the majority of patients admitted in ICCU (93.1%). 
Most of them belong to 4th and 6th decade. 
 
  
Table 3 
Risk factors 
 
Present Absent Risk Factors 
No. % No. % 
Smoking(134) among 
men 
77 57.5 57 42.5 
SHT 51 35.4 93 64.6 
DM 30 20.8 114 79.2 
Dyslipidemia 105 72.9 39 27.1 
CAD 16 11.1 128 88.9 
Menopause 9 90 1 10 
 
Smoking (in men), dyslipidemia and systemic hypertension were 
the major risk factors of patients in the study group. 
 
 
  
Table 4 
No. of Risk factors present in patients 
 
Patients No. of risk factors 
present No. % 
Nil 9 6.3 
1 45 31.5 
2 46 36.2 
3 31 21.7 
4 9 6.3 
5 3 2.1 
6 - - 
 
Number of patient with 1 or 2 risk factors formed 33.81%. 
 
 
  
 
Table 5 
Area of Infarct 
 
Patients Area of infarct 
No. % 
AWMI 95 66 
Others 39 27.1 
Both 10 6.9 
 
AWMI accounted for the majority (66%) of patients in study group. 
 
  
 
Table 6 
Thrombolysis 
 
Patients S.No. Thrombolysis 
No. % 
Successful thrombolysis 76 52.8 
Unsuccessful 
thrombolysis 
34 23.6 
1. 
Total 110 76.4 
2. Non Thrombolysis 34 23.6 
 
Two thirds in the study group underwent thrombolysis of which 
two thirds had successful thrombolysis defined as "50% ST segment 
resolution and or resolution of chest pain". 
 
CHARACTERISTICS OF PATIENTS AND INCIDENCE OF CLOT 
 
Table 7 
Age and Incidence of Clot 
 
LV Clot 
Present Absent 
Age Group Total Cases 
No. % No. % 
21-30 3 1 33.3 2 66.7 
31-40 17 8 47.1 9 52.9 
41-50 41 11 26.8 30 73.2 
51-60 46 9 19.6 37 80.4 
> 60 37 7 18.9 30 81.1 
Total 144 36 25 108 75 
Mean 
S.D. 
53.61 
11.25 
57.78 
10.08 
P 0.0448 
 
 Statistically significant relationship exists between age and 
incidence of LV Clot. 
 
 
  
 
Table 8 
Sex and Incidence of Clot 
 
LV Clot 
Present Absent 
Sex 
No. % No. % 
Male 34 94.4 100 92.6 
Female 2 5.6 8 7.4 
p 0.5229 
 
 No statistically significant relationship exists between sex and 
incidence of clot. 
 
 
 
 
 
 
 
Table 9 
Risk Factors and Incidence of Clot 
 
LV Clot 
Present 
(36) 
Absent (108) 
Risk Factors 
No. % No. % 
Smoking  
Yes 22 61.1 55 50.9 
No 14 38.9 53 49.1 
p 0.3853 
SHT  
Yes 15 41.7 36 33.3 
No 21 58.3 72 66.7 
p 0.4813 
DM  
Yes 7 19.4 23 21.3 
No 29 80.6 85 78.7 
p 0.8133 
Dyslipidemia  
Yes 26 72.2 79 73.1 
No 10 27.8 29 26.9 
p 0.9137 
CAD  
Yes 2 5.6 14 13 
No 34 94.4 84 87 
P 0.1812 
 
Table 10 
 
LV Clot 
Present 
(36) 
Absent 
(108) 
Risk Factors 
No. % No. % 
p 
Menopause  
Yes 2 5.6 7 6.5 
No 34 94.4 101 93.5
 
 
0.6007 
No. of  Risk factors   
Nil 2 5.7 7 6.5 0.6007(N.S.) 
1 10 28.6 35 32.4 0.7555(N.S.) 
2 10 28.6 36 33.3 0.6798(N.S.) 
3 11 31.4 20 18.5 0.1979(N.S.) 
4 2 5.7 7 6.5 0.6007(N.S.) 
5 - - 3 2.8 0.4189(N.S.) 
 
*NS – Not Significant 
 
 No statistically significant relationships exist between individual 
risk factors and LV Clot occurrence. 
 
 
  
 
Table 11 
KILLIP Classification and Incidence of Clot 
 
LV Clot 
Present Absent 
Killip Classification 
No. % No. % 
Nil 2 5.6 14 13 
I 8 22.2 61 56.5 
II 22 61.1 27 25 
III 1 2.8 2 1.9 
IV 3 8.3 4 3.7 
 
Incidence of LV Clot more in those under Killip Class II. 
 
  
 
Table 12 
Area of Infarct and Incidence of Clot 
 
LV Clot 
Present Absent 
Area of Infarct 
No. % No. % 
AWMI (95) 31 32.6 64 67.4 
IWMI(39) 1 2.7 38 97.3 
Both (10) 4 40 6 60 
P 0.0061 
 
Area of infarct and incidence of clot have significant relationship. 
 
Table 13 
Thrombolysis and Incidence of Clot 
 
LV Clot 
Present Absent 
Thrombolysis 
No. % No. % 
Successful thrombolysis 16 44.4 60 55.6 
Unsuccessful thrombolysis 8 22.2 26 24.1 
Total 24 66.6 86 79.7 
Non Thrombolysis 12 33.3 22 20.3 
Total 36 100 108 100 
P 0.174 (Not significant) 
 
 Incidence of thrombus in thrombolysed individual was 44.4% 
and 33.3% in non thrombolysed patients which was not statistically 
significant. 
 
  
 
Table 14 
Presence of MR and Incidence of Clot 
 
LV Clot 
Present Absent 
Presence of MR 
No. % No. % 
Present (38) 15 39.5 23 60.5 
Absent (106) 21 19.8 85 80.2 
P 0.029(Significant) 
                                                           
The presence of MR  on serial echo was found to have 
statistically significant relationship with development of LV clot.   
  
Table 15 
Median Delay and Incidence of Clot 
 
LV Clot 
Present Absent 
Median Delay 
No. % No. % 
< 6 hours 13 36.1 60 55.6 
6.1-12 12 33.3 43 43 
12.1-24 2 5.6 1 0.9 
> 24 9 25 4 3.7 
Mean delay in hours 
S.D. 
12.06 
9.87 
6.95 
4.34 
P 0.0059 
 
 Patients with LV clot have higher median delay than patients 
without LV clot and this difference is statically significant. 
 
  
 
Table 16 
Echo evaluation parameter and Incidence of Clot  
 
LVIDd LVEF EDV ESV FS WMSI LV  
Clot Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
Present 5.02 0.36 40.33 4.95 140.14 29.68 48.19 6.15 57.13 14.83 1.52 0.18
Absent 4.89 0.91 48.28 9.91 129 28.9 26.44 5.96 63.23 9.74 1.25 0.12
P 0.1268 
(Not 
significant) 
0.0001 
(Significant)
0.2582 
(Not 
Significant) 
0.0001 
(Significant)
0.5213 
( Not 
Significant) 
0.0001 
(Significant)
  
Statistically significant relationships exist between occurrences 
of LV Clot and ESV, WMSI, LVEF.  
 
  
 
Table No. 17 
Days from acute myocardial infarction and  
percentage of thrombosis 
 
Thrombolysis Days 
No. % 
1-7 17 47.2 
8-14 11 30.6 
15-28 8 22.2 
Total 36 100 
 
It was observed that most (47.2%) of the patients developed left 
ventricular thrombus within the first week of post infarct period. 
DISCUSSION 
 
144 Patients admitted to ICCU with acute myocardial infarction, 
in Government Rajaji Hospital, Madurai during the period of August 
2005 to July 2006 were included in the study. End point of the study 
was discharge from the ICCU one month after infarction. 
 
Age of the patients admitted to ICCU ranged from 21 – 80 years 
with a mean age of 57.6+12. 93.1% of the patients admitted to 
intensive coronary care unit were males. 
 
Serial Echo's when done at the time of admission and on Days 
14 and 28 to assess whether Echo cardiographic scores (data) are 
useful as predictors of LV thrombus occurrence. 
 
25%(36) of the patients developed LV thrombosis during the 
study. Of the 36 patients who developed LV thrombosis,16 patients 
(15%) of the thrombolysed group and 10 patients (29%) of the non 
thrombolsyed group had WMSI > 1.5. Of the remaining 10 patients 
who developed thrombus, 6 (5%) patients were thrombolysed and 4 
(12%) patients were  non thrombolysed, and their WMSI score was    
1-1.5.This indicates that the apparent decreased incidence of LV 
thrombus formation in thrombolysed patient is not due to thrombolysis 
per se, rather clearly depicts the impact of WMSI on development of 
LV thrombus. 
 
Patients with WMSI > 1 were found to have increased chance of 
development of LV thrombus, the risk being substantially increased for 
score > 1.5. 
 
36 patients who developed LV thrombus (both thrombolysed and 
non thrombolysed group) had high end systolic volume on base line 
Echo. Hence high end systolic volume in acute myocardial infarction is 
also an independent predictor of left ventricular thrombus. 
 
The incidence of left ventricular thrombi in our study was 25% 
which is lower than previously published data European Heart 
Journal (1993) 19, 908-916 A.D. Popovic et al. This is probably result 
of absence of long term follow up protocols in our study. 
 
36 patients who developed LV thrombus 31 (32.6%) had AWMI 
which agrees with earlier studies that document the rarity of LV 
thrombus in inferior wall infarct  (Lea and Febiger European Heart 
Journal 1994; 575-625). 
SUMMARY 
 
The “STUDY OF INTRACAVITARY THROMBUS IN 
THROMBOLYTIC ERA” was conducted among 144 patients admitted in 
ICCU, Govt.Rajaji  Hospital, Madurai. 
 
 From the patients who satisfied inclusion criteria,  serial echo’s were 
done at the time of admission(baseline) and on day 14 and day 28 after 
infarction to detect the occurrence of LV thrombus. The relationship between 
WMSI (Wall motion score index),site of infarct, elevated ESV and formation 
of thrombus was evaluated. 
 
 Significant statistical association was noted with respect to the 
following factors with incidence of LV thrombus as shown below: 
 47.1% in 4th decade,   
 33.3%in 3rd decade,  
 Anterior wall MI: 32.6%,   
 39.5% in the presence of MR,  
 High initial ESV at baseline echo  and 
 WMSI >1.5 
 
 No statistically significant relationship was noted with relation to sex, 
smoking, presence of systemic hypertension, diabetes mellitus and 
dyslipidemia,menopause and family h/o CAD and formation of LV Thrombus. 
 
  The study clearly indicates that in patients with AMI, high initial ESV 
at baseline echo and WSMI>1.5 are independent predictors of later 
development of LV thrombus. 
 
 
 
CONCLUSION 
 
• The incidence of intra cavitary thrombus in STEMI patients 
following thrombolysis was 21.81%. 
 
• Identification of high WMSI on admission (base line echo 
cardiogram) plays a definite role in predicting development of LV 
Thrombus. 
 
• The analysis revealed age, sex, smoking, systemic 
hypertension, diabetes mellitus, dyslipidemia, family history, 
CAD were not independent predictors of LV thrombus formation. 
 
• LV Thrombosis was associated with higher initial end systolic 
volume index, lower initial LV ejection fraction, killip class > 1, 
higher median delay, occluded infarct related artery, and non 
thrombolytic therapy. 
 
• It appears that determination of WMSI and end systolic volume 
can differentiate patient with acute STEM1 who would develop 
LV thrombosis from those who would not. 
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PROFORMA 
 
STUDY OF INTRA CAVITARY THROMBUS IN THROMBOLYTIC ERA 
 
 
Name :    Age :  Sex :  C.D. No.: 
Address :        I.P.No. : 
         DOA : 
         DOE : 
         DOHS : 
 
  DM     HT 
  SMOKING    CAD 
HLP  TC  TG  HDL-C VLDL-C LDL-C 
  MENOPAUSE   EMBOLISM 
  OTHERS 
IN HOSPITAL 
  CVA     DVT    
 HYPOTENSION 
  Killip Classification  I II III IV   LVF 
     ECG 
RHYTHM     Sinus     
 AF 
AREA OF INFARCT 
Median Delay 
 Success  Yes/No 
    50% ST resolution 
    Resolution of Chest pain 
 
ECHO EVALUATION 
IVSd    IVSs    LA 
LVIDd    LVIDs    AO 
LVPWd   LVPWs   RA 
EF    FS    RV 
ESV    EDV    SV 
MR 
Clot :  Location  Size   Mobility   
Other 
 
New Segment No. & Score 
01. Basal Anterior  
02. Basal Anterior septal  
03. Basal Inferior septal  
04. Basal inferior   
05. Basal Inferior Lateral  
06. Basal Anterior Lateral  
07. Mid Anterior  
08. Mid Anterior Septal  
09. Mid Inferior Septal  
10. Mid Inferior  
11. Mid Inferior Lateral  
12. Mid Anterior Lateral  
13. Apical Anterior  
14. Apical Septal  
15. Apical Inferior  
16. Apical Lateral  
17. True Apex  
 Total  
 
WMSI (Wall Motion Score Index) =   Total Score 
      No. of segments evaluated 
  NORMAL – 1     HYPOKINECTIC – 2         AKINETIC – 3 
  DYSKINETIC-4   ANEURYSM-5 
LVEF and Incidence of LV Clot
40.33
48.28
36
38
40
42
44
46
48
50
LVEF
Present Absent
ESV and Incidence of LV Clot
48.19
26.44
0
5
10
15
20
25
30
35
40
45
50
ESV
Present Absent
WMSI and Incidence of LV Clot
1.52
1.25
1
1.1
1.2
1.3
1.4
1.5
1.6
WMSI
Present Absent
Area of Infarct and Incidence of Clot
64
38
6
31
1 40
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20
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40
50
60
70
AWMI Others Both
Present
Absent
Present Absent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of MR and Incidence of Clot
21
85
15
23
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Present
Absent
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Days from acute myocardial infarction and percentage of 
thrombosis
47.2
30.6
22.2
0
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ge
Days
1-7 8-14 15-28
 ECHO CARDIOGRAPHIC PICTURE OF LV THROMBUS
A
Apical four-chamber view reveal a large 
laminar thrombus filling a subsdantial 
portion of the apex and adherant to the 
ventricular septum (Arrows - top panel).
The bottom panel denotes a smaller, more 
spherical   thrombus in the apex of the left 
ventricle.   
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6 6 M 2 1 2 1 3 3 2 6 1 1 2 1 2 4.6 68 130 42 22 1.24 2 1  
7 6 M 1 2 2 1 2 2 2 24 3 1 2 2 2 5.9 45 170 92 23 1.53 1 2 NT 
8 7 M 1 2 2 2 3 2 2 4.5 1 2 1 1 2 4.7 70 140 42 24 1.18 2 1  
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30 5 M 1 2 2 2 3 3 2 4 1 1 2 1 2 4.7 41 90 37 20 1.24 2 1  
31 6 M 1 2 1 2 2 3 2 5 1 1 2 1 2 4.6 56 136 44 28 1.24 2 1  
32 5 M 2 2 2 1 2 3 2 15 4 1 1 2 1 6.2 37 170 87 21 1.94 1 1  
33 6 M 1 2 2 2 3 2 2 4 2 1 2 1 2 4.6 40 97 38 21 1.29 2 1 AF 
34 4 M 1 2 2 1 2 3 2 24 2 1 2 1 2 6.6 34 176 94 19 1.76 1 2  
35 5 M 2 2 2 2 3 2 2 2.5 1 2 1 1 2 4.1 47 92 42 23 1.12 2 1  
36 6 M 2 2 2 2 3 2 2 4 2 1 2 1 2 4.8 53 192 52 24 1.24 2 2  
37 7 M 2 1 2 2 3 3 2 24 1 1 2 2 2 4.6 46 160 46 22 1.29 2 2  
38 5 M 1 1 1 1 2 3 2 2.5 2 1 2 1 2 6.2 35 180 94 20 1.53 1 1  
39 7 M 1 1 2 2 3 2 2 6.5 2 1 2 2 1 6.3 28 184 94 18 1.71 1 1  
40 7 M 2 1 2 2 3 2 2 6.5 2 1 2 2 2 6.5 35 167 86 19 1.47 1 1 
NT 
CVA 
N 
41 7 M 1 1 2 2 2 3 2 11 1 2 1 2 2 4.4 28 97 34 18 1.35 2 2  
42 6 M 1 1 1 2 2 2 2 4 1 2 1 1 2 4 52 140 42 26 1.24 2 2  
43 5 M 2 1 1 2 2 3 2 3 1 1 2 1 2 4.7 35 82 43 19 1.47 2 2  
44 7 M 2 2 2 2 2 3 2 6.5 1 1 1 2 1 4.3 67 140 37 29 1.12 2 2  
45 6 M 2 1 2 2 2 2 2 6 2 1 2 1 2 5.8 47 170 87 23 1.53 1 2  
46 3 M 1 1 2 1 3 3 1 6 3 1 1 1 2 4.6 74 106 35 30 1.35 2 2  
47 7 M 1 1 1 2 3 2 2 3.5 2 1 2 1 2 5.7 49 156 64 21 1.47 2 2  
48 5 M 1 2 2 1 2 3 2 6 1 1 2 1 2 5.7 44 160 54 22 1.47 2 2  
49 6 M 1 1 1 2 3 3 2 9 1 1 2 2 1 5.6 42 160 61 21 1.59 2 2  
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50 6 M 2 1 1 1 3 3 1 11 2 1 2 2 1 7.2 26 170 64 17 1.47 2 1 LVA 
51 6 M 1 2 2 2 3 3 2 6 2 1 2 1 2 5.2 39 163 55 20 1.47 2 1  
52 6 M 1 2 2 1 3 3 2 8 2 2 1 2 1 5.3 54 110 42 25 1.12 2 2  
53 7 M 2 1 2 2 2 2 2 6 1 2 1 1 2 4.2 60 125 37 28 1.18 2 2  
54 6 F 2 1 1 1 3 3 2 11 2 2 1 2 1 4.3 55 126 40 26 1.12 2 2  
55 8 M 2 1 2 2 2 2 2 6 1 2 1 1 2 3.9 51 160 46 24 1.12 2 2  
56 6 M 2 2 2 1 3 2 2 24 1 1 2 2 2 5.8 53 162 42 25 1.12 2 2  
57 9 M 2 1 2 2 2 2 2 1.45 2 2 1 2 2 4 54 140 40 25 1.12 2 2  
58 9 M 1 2 2 2 3 2 1 7 2 1 2 2 1 4.2 46 160 47 24 1.35 2 2  
59 7 M 2 1 2 2 3 2 2 9 2 2 1 2 1 4.3 50 134 51 24 1.18 2 2  
60 5 M 1 2 2 2 2 2 2 3 1 1 2 1 2 4.6 56 104 37 25 1.24 2 2  
61 4 M 2 2 2 2 2 2 2 11 2 2 1 1 2 4.7 53 126 35 25 1.12 2 2  
62 5 M 2 2 2 2 3 2 1 7 2 1 2 1 2 6 40 168 90 21 1.35 1 2  
63 6 M 1 2 1 2 2 2 2 4 2 2 1 1 2 4.8 49 160 66 23 1.12 2 2 UK 
64 5 M 1 2 2 2 2 2 2 3 2 1 2 1 2 6 40 164 88 22 1.35 1 2  
65 5 M 1 2 2 2 3 2 2 12 1 1 2 2 1 4.3 44 160 49 22 1.12 2 2  
66 7 M 1 2 2 2 2 2 2 4 1 2 1 1 2 5 43 162 52 21 1.35 2 1  
67 4 M 1 1 2 2 3 3 2 6 4 1 1 2 2 4.8 42 164 54 21 1.35 2 2  
68 7 F 2 1 1 1 3 3 1 4.5 2 1 2 1 2 5.8 42 178 56 21 1.47 1 1  
69 6 M 1 1 2 2 3 2 2 2.5 1 1 2 2 1 3.8 40 164 48 21 1.24 2 2  
70 6 M 1 2 2 2 3 2 2 24 2 1 2 2 2 3.9 54 130 38 24 1.12 2 2  
71 5 M 2 2 2 2 3 2 2 2.45 1 1 2 1 2 4.7 53 137 47 25 1.59 2 2  
72 6 M 1 1 2 2 3 2 2 2.5 1 1 2 1 2 5.1 64 90 38 28 1.35 2 2  
73 6 M 1 1 2 1 2 3 2 5 4 2 1 1 2 5 47 140 42 27 1.12 2 2  
74 5 M 1 2 2 1 2 2 2 12 5 1 2 2 2 4.6 46 160 46 22 1.29 2 2  
75 8 M 2 2 1 2 2 2 2 5 4 2 1 1 2 4.9 39 140 42 26 1.24 2 2  
76 6 M 1 2 1 1 3 2 2 10 1 1 2 2 1 6.4 35 93 84 23 1.53 1   
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77 7 M 2 2 1 1 3 2 2 11 5 1 2 2 1 5.5 52 160 45 22 1.29 2 2  
78 6 M 1 2 2 2 3 2 1 7 2 1 2 1 2 4 51 138 41 24 1.24 2 2  
79 7 M 2 2 1 2 2 2 2 7 1 2 1 2 1 4.2 49 135 50 24 1.18 2 2  
80 6 F 2 1 1 1 3 2 1 8 1 2 1 1 2 4.7 48 158 64 22 1.12 2 2  
81 7 M 2 1 1 1 3 2 2 10 2 1 2 2 1 6.6 32 171 92 22 1.53 1 2  
82 5 M 2 2 2 1 2 3 2 10 5 2 1 1 2 4.3 56 103 38 25 1.24 2 2  
83 7 M 2 2 2 1 3 3 2 4 2 2 1 1 2 4.2 30 96 35 18 1.24 2 2  
84 6 M 1 1 2 1 2 2 2 3 2 1 2 1 2 5.9 41 170 88 24 1.71 1 1  
85 6 M 1 1 2 2 3 2 2 6 4 1 2 2 1 5.8 42 92 84 23 1.53 1 2  
86 5 M 1 2 2 1 2 2 2 5.5 2 1 2 1 2 6.1 42 160 45 22 1.29 2 2  
87 4 M 1 2 2 2 3 2 2 8.5 1 2 1 1 2 4.9 61 90 38 28 1.35 2 2  
88 7 M 1 2 2 2 2 2 1 12 3 1 2 2 1 5 35 134 49 23 1.18 2 2  
89 6 M 1 2 2 2 3 2 2 7 1 1 2 1 2 4.5 54 140 41 27 1.24 2 2  
90 5 M 1 1 2 1 2 3 2 12 1 2 1 2 2 5.8 41 170 93 22 1.53 1 2 NT 
91 6 M 1 2 1 1 3 2 2 6 1 2 1 2 1 6.4 43 136 37 24 1.24 2 2  
92 6 M 2 2 1 2 3 2 1 6.5 1 2 1 2 1 5.3 54 146 43 23 1.18 2 2  
93 6 M 2 2 1 2 2 2 2 12 2 1 2 2 2 5.8 41 142 79 24 1.59 1 2 NT 
94 5 M 2 1 2 2 3 2 2 9 1 1 2 2 2 5.7 58 136 41 22 1.24 2 2  
95 4 M 1 2 2 1 3 2 2 2.15 2 1 2 2 2 4.8 50 146 44 23 1.18 2 2  
96 5 M 2 1 1 2 2 3 2 12 1 2 1 2 2 4.3 63 136 41 23 1.12 2 2  
97 7 M 1 2 2 2 3 2 2 6.5 1 1 1 2 2 4.6 49 130 42 22 1.24 2 2  
98 6 M 1 2 2 2 2 3 2 4.15 1 1 2 1 2 5.9 39 173 84 23 1.35 1   
99 7 M 2 2 2 2 3 3 2 14 1 1 2 2 2 3.7 56 131 37 24 1.24 2 2  
100 7 M 1 2 2 2 2 3 2 11.5 2 2 1 2 1 4.6 48 158 67 23 1.12 2 2  
101 4 M 1 2 1 2 2 2 2 5 2 1 2 1 2 4.7 34 161 52 21 1.35 2 2  
102 5 M 1 1 2 2 3 3 2 4.5 4 2 1 1 2 4.9 42 132 39 24 1.12 2 G2  
103 7 F 2 2 2 2 2 2 2 6.5 1 1 2 2 1 5.5 35 156 64 22 1.47 2 G2  
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104 6 M 1 1 2 2 2 2 2 6.5 1 2 1 1 2 5.7 49 161 41 25 1.12 2 2  
105 5 M 1 2 2 2 3 3 2 5.5 2 1 2 1 2 6.2 38 156 62 21 1.59 1 G2  
106 6 M 1 2 2 2 3 2 2 4.5 1 1 2 1 2 3.3 55 164 36 24 1.24 2 2  
107 5 M 1 1 1 2 2 3 2 5 1 2 1 2 1 5.7 65 163 47 22 1.24 2 2  
108 8 M 2 2 2 2 2 2 2 9 1 2 1 2 1 5.1 40 160 46 21 1.24 2 2  
109 6 M 2 2 2 2 3 2 2 10 1 2 1 2 1 4.9 57 133 39 23 1.12 2 2  
110 4 M 1 2 2 2 3 2 2 7.5 1 1 2 1 2 5.8 49 130 53 24 1.18 1 2  
111 4 M 1 2 2 2 2 2 1 9 1 1 2 2 1 5.8 42 161 57 21 1.24 1 2  
112 8 F 2 2 2 2 3 2 2 3.5 2 1 2 2 1 4.3 53 139 53 24 1.18  2  
113 7 M 1 2 2 2 2 2 2 8 1 1 2 1 2 4.7 41 97 41 22 1.35 2 2  
114 6 M 2 2 2 2 2 2 2 6 1 1 2 2 2 5.9 36 95 78 24 1.41 1 G1 NT 
115 7 M 2 2 2 2 2 2 2 24 5 1 2 2 2 7.5 39 98 83 23 1.35 1 2 NT 
116 4 M 1 2 2 2 2 3 2 24 5 1 2 2 2 5.8 36 142 79 23 1.59 1 2 NT 
117 5 M 1 2 2 2 3 2 2 10 1 1 2 2 1 4.6 37 87 40 22 1.35 2 2  
118 4 M 2 1 2 2 2 3 2 4 1 2 1 1 2 5.3 51 143 43 24 1.18 2 2  
119 5 M 2 2 2 2 3 2 2 3 2 1 2 1 2 5.8 41 140 80 23 1.59 1 2  
120 3 M 1 2 2 2 3 2 2 5 1 1 2 1 2 5.4 43 95 62 22 1.21 2 2  
121 7 F 1 2 2 2 3 2 2 4.5 1 2 1 1 2 4.9 60 137 40 23 1.12 2 2  
122 4 M 2 2 2 2 2 2 2  1 1 2 1 2 4.2 54 130 47 24 1.18 2 2  
123 6 M 2 2 2 2 3 2 2 5.5 1 1 2 2 2 4.7 46 86 46 24 1.24 2 2  
124 5 M 2 2 2 2 2 3 2 6.5 1 1 2 2 2 6.7 28 70 37 17 1.29 2 2  
125 5 M 1 2 2 2 2 2 2 3.5 1 1 2 2 2 5.1 44 96 64 23 1.24 2 2  
126 5 M 1 2 2 2 2 2 2 7 1 1 2 2 2 4.2 54 131 96 24 1.18 2 2  
127 5 M 2 2 2 2 2 2 2 4.5 1 1 2 1 2 4 52 137 43 24 1.24 2 2  
128 6 M 2 2 2 2 3 3 2 6 1 2 1 1 2 5 46 139 41 26 1.12 2 2  
129 5 M 1 1 2 2 2 2 2 24 1 1 2 2 2 5.8 38 141 81 26 1.24 1 2 NT 
130 4 M 1 2 2 2 2 2 2 24 1 1 2 1 2 5.8 35 170 91 22 1.57 1 2  
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131 5 M 1 1 2 2 3 2 2 4 2 1 2 1 2 5.4 42 98 37 25 1.24 2 2  
132 6 M 2 2 2 1 3 3 2 24 1 1 2 2 1 5.6 36 97 36 22 1.24 2 2  
133 5 M 1 2 2 2 2 2 2 4.5 2 1 2 1 2 4.6 42 87 37 29 1.35 2 2  
134 5 M 2 2 2 2 2 3 2 7 1 1 2 2 1 5.2 63 90 38 27 1.35 2 2  
135 6 M 2 1 2 2 2 2 2 4 1 1 2 1 2 4.8 41 141 49 22 1.24 2 2  
136 4 M 1 1 2 2 3 2 2 5.5 2 1 2 1 2 5.9 41 172 81 23 1.53 1 2  
137 5 M 2 2 1 2 3 2 2 7.5 1 1 2 2 1 5.4 53 157 44 22 1.29 2 2  
138 4 M 1 1 2 1 2 2 2 8 2 1 2 2 1 5.7 49 135 59 24 1.18 1 2  
139 5 M 2 2 2 2 2 3 2 3.5 1 1 2 1 2 3.9 52 137 42 24 1.24 2 2  
140 6 M 1 1 2 2 2 2 2 6 1 1 2 1 2 5.4 51 157 44 22 1.29 2 2  
141 4 M 2 2 2 2 3 2 2 7.5 2 1 2 1 2 4.6 56 104 37 25 1.24  2  
142 5 M 1 2 1 2 3 2 2 6.5 2 1 1 2 2 5.9 40 165 87 21 1.35 2 G1  
143 6 M 2 1 2 2 2 2 2 8 1 1 2 2 1 3.7 40 161 48 21 1.24  2  
144 5 M 1 2 2 1 3 3 1 5 2 1 2 1 2 6.2 38 175 93 21 1.47 2 2  
 
Abbreviations in Master Chart 
 
Risk Factor  Lipid Profile (LDL, HDL, TGL in mgs% ) Normal HDL  >50 in female ; >40 male 
Present – 1   If Decreased = 1    Normal LDL < 160 (if 1 or No risk factor) < 130  (2 or > risk factor) 
Absent - 2   If Normal = 2                          < 100 if diabetes present 
   If Increased = 3    Normal TGL < 150 
 
Thrombolysis successful  = 1      LV clot present  = 1 
Thrombolysis unsuccessful = 2        LV clot absent            = 2 
TX = Thrombolysed  
